CS1 Administration
Phase 2Completed 0 watching 0 views this week⚡ Active
47
Development Stage
✓
Pre-clinical✓
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Pulmonary Arterial Hypertension
Conditions
Pulmonary Arterial Hypertension
Trial Timeline
May 5, 2022 → Aug 1, 2024
NCT ID
NCT05224531About CS1 Administration
CS1 Administration is a phase 2 stage product being developed by Cereno Scientific for Pulmonary Arterial Hypertension. The current trial status is completed. This product is registered under clinical trial identifier NCT05224531. Target conditions include Pulmonary Arterial Hypertension.
Hype Score Breakdown
Clinical
17
Activity
12
Company
5
Novelty
5
Community
5
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05224531 | Phase 2 | Completed |
Competing Products
20 competing products in Pulmonary Arterial Hypertension